Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.
Nucleic Acid Ther. 2013 Oct;23(5):332-43. doi: 10.1089/nat.2013.0424.
The human noncoding RNA gene RGM249 has been shown to regulate the degree of cancer cell differentiation. In this study, we investigated the effects of 3 microRNA-like molecules digested from RGM249 on the loss of malignant properties in cancer cells in immunodeficient KSN/Slc mice. We utilized small interfering RNAs (siRNAs) alone or in combination with a cationized drug delivery system (DDS) consisting of atelocollagen or gelatin hydrogel microspheres. The results demonstrated growth inhibition and apoptosis and the inhibition of both neovascularization and metastasis, indicating that the DDSs effectively infiltrated the majority of tumor cells in vivo. Systemic administration of the 3 siRNAs inhibited the metastatic ability of malignant cells. Cotransfection of these siRNAs exerted a regulatory effect upon the genes involved in differentiation, pluripotency, and proliferation in cancer cells. These results suggest that RGM249-derived oligonucleotides may be involved in the regulation of metastasis, proliferation, and differentiation in vivo, and that the tested siRNAs may therefore represent a new anticancer therapeutic approach.
人类非编码 RNA 基因 RGM249 已被证明可以调节癌细胞分化程度。在这项研究中,我们研究了从 RGM249 消化得到的 3 种 miRNA 样分子对免疫缺陷 KSN/Slc 小鼠中癌细胞恶性特性丧失的影响。我们单独使用小干扰 RNA (siRNA) 或与由鱼精蛋白或明胶水凝胶微球组成的阳离子药物递送系统 (DDS) 联合使用。结果表明生长抑制和细胞凋亡以及新生血管生成和转移的抑制,表明 DDSs 有效地在体内渗透到大多数肿瘤细胞中。这 3 种 siRNA 的系统给药抑制了恶性细胞的转移能力。这些 siRNA 的共转染对癌细胞中涉及分化、多能性和增殖的基因发挥了调节作用。这些结果表明,RGM249 衍生的寡核苷酸可能参与体内转移、增殖和分化的调节,因此测试的 siRNA 可能代表一种新的抗癌治疗方法。